[email protected]

国际临床研究杂志

International Journal of Clinical Research

您当前位置：首页 > 精选文章

International Journal of Clinical Research. 2022; 6: (2) ; 10.12208/j.ijcr.20220084 .

Observation of clinical effect of compound probiotics in improving intestinal health
复合益生菌改善肠道健康的临床效果观察

作者： 侯建亮 *, 潘仕城, 付继先, 赵广义, 吴雪洁

山东中科嘉亿生物工程有限公司 山东青州

*通讯作者： 侯建亮,单位：山东中科嘉亿生物工程有限公司 山东青州；

收录截图（CNKI-Scholar）

引用本文: 侯建亮, 潘仕城, 付继先, 赵广义, 吴雪洁 复合益生菌改善肠道健康的临床效果观察[J]. 国际临床研究杂志, 2022; 6: (2) : 174-177.
Published: 2022/4/26 14:17:30

摘要

目的 观察复合益生菌改善肠道健康的临床效果。方法 回顾性选取2020年2月-2021年2月本院溃疡性结肠炎患者100例，依据用药方法分为美沙拉嗪单独用药组（单独用药组）、美沙拉嗪联合复合益生菌用药组（联合用药组）两组，各50例，统计分析两组症状评分、肠镜分级、血清TNF-α水平、肠粘膜屏障功能、临床疗效、肠道菌群数量、不良反应发生情况。结果 用药后，联合用药组患者的症状评分、肠镜分级、血清TNF-α水平、L/M均低于单独用药组（P<0.05）。联合用药组患者的总有效率90.00%（45/50）高于单独用药组70.00%（35/50）（χ2=6.250，P<0.05）。用药后，联合用药组患者的大肠杆菌、粪肠球菌计数均低于单独用药组（P<0.05），乳酸杆菌、双歧杆菌计数均高于单独用药组（P<0.05）。两组患者的不良反应发生率16.00%（8/50）、10.00%（5/50）之间的差异不显著（χ2=0.796，P>0.05）。结论 复合益生菌改善肠道健康的临床效果好。

关键词： 溃疡性结肠炎；美沙拉嗪；复合益生菌；肠道健康；不良反应

Abstract

Objective: To observe the clinical effect of compound probiotics in improving intestinal health.
Methods A total of 100 patients with ulcerative colitis in our hospital from February 2020 to February 2021 were retrospectively selected, and they were divided into mesalazine single medication group (single medication group) and mesalazine combined with compound probiotics medication group ( Combined medication group) two groups, 50 cases in each group. Symptom scores, colonoscopy grades, serum TNF-α levels, intestinal mucosal barrier function, clinical efficacy, intestinal flora, and adverse reactions were statistically analyzed in the two groups.
Results After treatment, the symptom score, colonoscopy grade, serum TNF-α level and L/M in the combined treatment group were lower than those in the single treatment group (P<0.05). The total effective rate of the patients in the combined drug group was 90.00% (45/50) higher than that in the single drug group (70.00% (35/50) (χ2=6.250, P<0.05). After treatment, the counts of Escherichia coli and Enterococcus faecalis in the combined treatment group were lower than those in the single treatment group (P<0.05), and the counts of Lactobacillus and Bifidobacterium were higher than those in the single treatment group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups at 16.00% (8/50) and 10.00% (5/50) (χ2=0.796, P>0.05).
Conclusion   The clinical effect of compound probiotics in improving intestinal health is good.

Key words： ulcerative colitis; mesalazine; compound probiotics; intestinal health; adverse reactions

参考文献 References

[1] 毛丙永,崔树茂,潘明罗,等. 复合益生菌制剂对人体肠道菌群组成的调节作用[J]. 现代食品科技,2021,37(11): 8-13,113.

[2] 刘冠兰,冯勋,朱文韬,等. 复合益生菌粉对人体肠道菌群多样性的作用[J]. 兰州大学学报（医学版）, 2021, 47(1) :8-15. 

[3] 孙博超,杨运楷,李玉宏,等. 饲料中添加复合芽孢杆菌对凡纳滨对虾抗病毒感染能力及抗病基因表达的影响[J]. 渔业科学进展,2019,40(3):113-121.

[4] 余中节,赵洁,宋宇琴,等. 罗伊氏乳杆菌肠道分离株的遗传多样性研究[J]. 微生物学报,2019,59(9):1786-1797.

[5] 肖铃. 益生菌联合康复新液对于活动期轻中度溃疡性结肠炎的治疗效果分析[J]. 中国处方药,2018,16(2): 66-67. 

[6] 陈琳,张大超,童星,等. 老年人肠道功能性固体饮料的工艺研究[J]. 食品工业,2017,38(12):97-100.

[7] 陈张华,邓俊良. 复合抗菌肽对断奶仔猪肠道菌群和pH值的影响[J]. 畜牧与兽医,2017,49(11):109-113.

[8] 陈刚,鲍秀畸,颜玉,等. 益生菌对经免疫复合法诱导的大鼠溃疡性结肠炎TNF-α、IL-4的表达影响[J]. 黑龙江医药科学,2018,41(3):49-51. 

[9] 林易里. 美沙拉嗪联合肠道益生菌对溃疡性结肠炎的治疗价值分析[J]. 中外医学研究,2020,18(10):120-121.

[10] 莫燕娇. 益生菌在溃疡性结肠炎的疗效分析[J]. 世界复合医学,2020,6(4):169-171.